SG10201913952TA - Liquid protein formulations containing viscosity-lowering agents - Google Patents

Liquid protein formulations containing viscosity-lowering agents

Info

Publication number
SG10201913952TA
SG10201913952TA SG10201913952TA SG10201913952TA SG10201913952TA SG 10201913952T A SG10201913952T A SG 10201913952TA SG 10201913952T A SG10201913952T A SG 10201913952TA SG 10201913952T A SG10201913952T A SG 10201913952TA SG 10201913952T A SG10201913952T A SG 10201913952TA
Authority
SG
Singapore
Prior art keywords
formulations containing
lowering agents
protein formulations
liquid protein
containing viscosity
Prior art date
Application number
SG10201913952TA
Other languages
English (en)
Inventor
Alyssa Larson
Kevin Love
Alisha Weight
Alan Crane
Robert Langer
Alexander Klibanov
Original Assignee
Eagle Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biologics Inc filed Critical Eagle Biologics Inc
Publication of SG10201913952TA publication Critical patent/SG10201913952TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
    • A61G3/00—Ambulance aspects of vehicles; Vehicles with special provisions for transporting patients or disabled persons, or their personal conveyances, e.g. for facilitating access of, or for loading, wheelchairs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
SG10201913952TA 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents SG10201913952TA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361876621P 2013-09-11 2013-09-11
US201461940227P 2014-02-14 2014-02-14
US201461943197P 2014-02-21 2014-02-21
US201461946436P 2014-02-28 2014-02-28
US201461988005P 2014-05-02 2014-05-02
US201462008050P 2014-06-05 2014-06-05
US201462026497P 2014-07-18 2014-07-18
US201462030521P 2014-07-29 2014-07-29

Publications (1)

Publication Number Publication Date
SG10201913952TA true SG10201913952TA (en) 2020-03-30

Family

ID=51626611

Family Applications (6)

Application Number Title Priority Date Filing Date
SG10201913952TA SG10201913952TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201913950XA SG10201913950XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201806539XA SG10201806539XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG11201601730TA SG11201601730TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201809401XA SG10201809401XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG11201601728YA SG11201601728YA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids

Family Applications After (5)

Application Number Title Priority Date Filing Date
SG10201913950XA SG10201913950XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201806539XA SG10201806539XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG11201601730TA SG11201601730TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201809401XA SG10201809401XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG11201601728YA SG11201601728YA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids

Country Status (16)

Country Link
US (12) US9833513B2 (ru)
EP (7) EP3043774B1 (ru)
JP (11) JP6469113B2 (ru)
KR (5) KR102651018B1 (ru)
CN (7) CN110496099B (ru)
AU (10) AU2014318637B2 (ru)
CA (4) CA2923843C (ru)
ES (4) ES2959451T3 (ru)
HK (5) HK1225980A1 (ru)
IL (4) IL275388B1 (ru)
MX (6) MX2016003182A (ru)
RU (2) RU2710542C2 (ru)
SG (6) SG10201913952TA (ru)
SI (4) SI3043774T1 (ru)
WO (4) WO2015038777A1 (ru)
ZA (4) ZA201601968B (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080513A1 (es) 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
MX2013011385A (es) 2011-04-01 2014-03-13 Immunogen Inc Moleculas de union a cd37 y sus inmunoconjugados.
US20140348719A1 (en) * 2013-03-14 2014-11-27 Bureau Veritas Pharmaceutical compound stabilizing filter compositions and methods of making and using same
CN110496099B (zh) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
CN112353943A (zh) * 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
MX2017004306A (es) 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
JP6979877B2 (ja) * 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
TW202340452A (zh) * 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
LT3769781T (lt) * 2015-08-19 2023-06-12 Astrazeneca Ab Stabili anti-ifnar1 kompozicija
WO2017040247A1 (en) 2015-08-28 2017-03-09 Immunogen, Inc. Antibodies and assays for detection of cd37
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA3129181C (en) * 2015-10-23 2023-10-31 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP2018534930A (ja) * 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
EP3397281B1 (en) * 2015-12-29 2020-09-09 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab
CN105699555B (zh) * 2016-03-24 2018-09-11 中国标准化研究院 一种丙烯基乙基愈创木酚的液相色谱制备方法
MX2018012651A (es) * 2016-04-25 2019-01-30 Medimmune Llc Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4).
SG11201809786TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna monoclonal antibodies targeting il-6 and cd126
EP3761035B1 (en) * 2016-08-18 2024-02-14 Regeneron Pharmaceuticals, Inc. Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
US10463733B1 (en) 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US11274137B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11382976B1 (en) 2016-10-04 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11385201B1 (en) 2019-09-30 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274289B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274163B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
CN117244056A (zh) * 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
TW202308683A (zh) * 2016-11-02 2023-03-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
WO2018152165A1 (en) * 2017-02-16 2018-08-23 Reform Biologics, Llc Excipient compounds for protein processing
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
EP3615065A1 (en) * 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
AU2018290633B9 (en) * 2017-06-30 2021-04-01 Korea Advanced Institute Of Science And Technology Conjugate of VEGF-Grab protein and drug, and use thereof
BR112020003498A2 (pt) * 2017-08-22 2020-08-25 Biogen Ma, Inc. composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6)
MX2020002429A (es) * 2017-09-05 2020-07-13 Merck Sharp & Dohme Compuestos para reducir la viscosidad de las formulaciones biologicas.
MA50582A (fr) * 2017-11-07 2020-09-16 Alphacore Pharma Llc Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés
JP7425726B2 (ja) * 2017-11-17 2024-01-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
CN108096185A (zh) * 2017-12-20 2018-06-01 珠海冀百康生物科技有限公司 一种速效胰岛素制剂及其制备方法
KR102493469B1 (ko) * 2018-03-07 2023-02-07 코메라 라이프 사이언시스, 인코포레이티드 단백질 제형을 위한 부형제 화합물
AU2019254483A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
WO2020017901A1 (ko) * 2018-07-19 2020-01-23 (주)셀트리온 안정한 액체 약제학적 제제
WO2020106948A1 (en) * 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
US11058770B1 (en) * 2019-01-24 2021-07-13 United States Of America As Represented By The Secretary Of The Air Force Ultrastable antibody ionic liquids
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
CA3154653A1 (en) * 2019-09-17 2021-03-25 Merck Patent Gmbh Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
IL301024A (en) * 2020-09-01 2023-05-01 I2O Therapeutics Inc Ionic liquid formulations for the treatment of diabetes
CN113249358B (zh) * 2021-05-14 2022-10-14 天津大学 一种利用离子液体调控溶菌酶晶型的方法
EP4362980A2 (en) * 2021-07-01 2024-05-08 Upkara, Inc. Superconcentrated formulations of bioactive agents
CN115350330B (zh) * 2022-09-01 2023-10-20 北京化工大学 一种负电性小分子调控的表面在蛋白差异性黏附上的应用

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190082A (en) 1877-04-24 Improvement in apparatus for cooling liquids
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (da) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogifremgangsmåde til fremstilling af adrenocorticotropt aktive nonadecapeptidamider eller syreadditionssalte eller kompleksforbindelser deraf.
BE757195A (fr) 1969-10-07 1971-03-16 Century Disposable Devices Seringue servant a injecter un melange fraichement prepare de poudre etde liquide
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3650349T2 (de) 1985-03-15 1995-12-14 Antivirals Inc Immunotestmittel für polynukleotid und verfahren.
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (ja) 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd エリスロポエチン皮下又は筋肉投与剤
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (ja) * 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ プレフィルドシリンジおよびその包装体
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (ru) 1996-10-16 2000-09-09 Alza Corp
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP4460762B2 (ja) * 1997-10-15 2010-05-12 旭化成ファーマ株式会社 トロンボモジュリン水溶液注射剤の貯蔵・流通時の品質保持方法
JP3480941B2 (ja) 1997-10-22 2003-12-22 中外製薬株式会社 ＴＧＦ−β阻害物質のスクリーニング方法
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (fr) 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (de) 1999-07-29 2003-09-10 Wilhelm A. Keller Kartuschen-Austraggerät mit Antrieb für dynamischen Mischer
HU227347B1 (en) 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1339442A4 (en) 2000-11-30 2006-12-27 Biovalve Technologies Inc INJECTION SYSTEMS
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
AU2002257295B2 (en) 2001-05-16 2008-06-12 Biomarin Pharmaceutical Inc. Destruction of prions using vibriolysin or variants thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2003011786A1 (en) 2001-08-02 2003-02-13 3M Innovative Properties Company Glass-ceramics
JP4167820B2 (ja) 2001-10-19 2008-10-22 アルインコ株式会社 デッキプレート走行台車
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
KR20050038008A (ko) * 2002-07-31 2005-04-25 알자 코포레이션 주사용 저장형 조성물 및 이의 용도
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
JP2006522133A (ja) 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2004092361A1 (en) 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Process for isolating and purifing ovine hyaluronidase
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US7993872B2 (en) 2003-06-18 2011-08-09 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
CN1206344C (zh) 2003-07-28 2005-06-15 中国海洋大学 一种用细菌生产岩藻聚糖硫酸酯酶的方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2007523050A (ja) * 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
AU2005258077C1 (en) 2004-06-21 2012-10-25 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
ES2346212T3 (es) 2004-11-25 2010-10-13 Chr. Hansen A/S Metodo para la preparacion de una laca de acido carminico.
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
CN103271083B (zh) 2005-10-07 2017-08-11 阿拉巴马大学 多功能离子液体组合物
CN100416002C (zh) * 2005-10-26 2008-09-03 曲新华 污水再生利用装置
DK1962886T4 (da) 2005-12-20 2022-05-02 Bristol Myers Squibb Co Stabile proteinformuleringer
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN1823768A (zh) * 2006-01-09 2006-08-30 徐新盛 西咪替丁冻干组合物
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
ITMI20061030A1 (it) 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
CN101689450B (zh) 2007-07-20 2012-07-18 应用材料公司 等离子体工艺设备中用于至射频驱动电极的气体传递的射频扼流器
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
CA2696049A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
ES2403413T3 (es) 2007-10-16 2013-05-17 Pharmacyclics, Inc. Manufactura, composiciones y usos del modulador del factor de coagulación Vlla
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
WO2009086062A1 (en) 2007-12-21 2009-07-09 Lyotropic Therapeutics, Inc. Stabilized formulations of peptides and proteins
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20120251615A1 (en) * 2008-01-18 2012-10-04 Horst Kief Agent for intra-articular injection
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) * 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
TWI342781B (en) * 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
MX2011009306A (es) 2009-03-06 2011-10-13 Genentech Inc Formulacion con anticuerpo.
CA2760185A1 (en) 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
WO2010132047A1 (en) 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
JPWO2010134345A1 (ja) 2009-05-20 2012-11-08 積水メディカル株式会社 血液凝固時間延長剤
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2769221A1 (en) * 2009-08-04 2011-02-10 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010296017C1 (en) 2009-09-17 2013-09-19 Takeda Pharmaceutical Company Limited Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2011050000A2 (en) 2009-10-20 2011-04-28 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2548772C2 (ru) 2009-11-20 2015-04-20 Биокон Лимитед Составы антитела
US9289381B2 (en) * 2009-12-03 2016-03-22 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
CN102770539B (zh) 2009-12-10 2016-08-03 明尼苏达大学董事会 Tal效应子介导的dna修饰
WO2011083110A2 (en) 2010-01-08 2011-07-14 Chanel Parfums Beaute Use of at least one extract of flowers of camellia japonica alba plena for moisturizing the skin
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
CA2789061A1 (en) 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions
CN102946861B (zh) * 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
SG183983A1 (en) * 2010-03-17 2012-10-30 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
EP2552482A2 (en) * 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
CN101851267A (zh) 2010-04-22 2010-10-06 江南大学 一种抗体保护剂及其应用
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
SG10201912670XA (en) * 2010-05-14 2020-02-27 Amgen Inc High concentration antibody formulations
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
US8936827B2 (en) 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
JP2014510152A (ja) 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
EA201391488A1 (ru) 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
RU2618159C2 (ru) 2011-05-12 2017-05-02 БАЙЕР ХелсКер ЛЛСи Система введения жидкости, имеющая различные системы для управления процедурой инъекции
RU2485133C2 (ru) 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Белково-полипептидный комплекс, обладающий тканеспецифическим регенеративно-репаративным и омолаживающим действием на кожную ткань, способ его получения и фармацевтическая композиция на его основе
CN102349895B (zh) * 2011-09-28 2013-04-10 海南良方医药有限公司 一种注射用西咪替丁组合物及其制备方法
EP2771299B1 (en) 2011-10-25 2017-12-13 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX352823B (es) 2011-10-28 2017-12-04 Integritybio Inc Formulaciones de proteinas que contienen aminoacidos.
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
JP2015506372A (ja) 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
DK3401400T3 (da) 2012-05-25 2019-06-03 Univ California Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
US10010513B2 (en) 2012-05-25 2018-07-03 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
MA37777B1 (fr) 2012-06-21 2017-07-31 Ucb Pharma Sa Préparation pharmaceutique
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
WO2014023709A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
WO2014160083A1 (en) 2013-03-13 2014-10-02 Applied Cardiovascular Solutions, Llc. Methods, compositions, and devices for the occlusion of cavities and passageways
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
CN110496099B (zh) * 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
MX2017004306A (es) * 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
US10812184B1 (en) 2019-04-03 2020-10-20 Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville Signal analysis systems and methods

Also Published As

Publication number Publication date
ZA202102906B (en) 2023-12-20
SG11201601730TA (en) 2016-04-28
US20180085463A1 (en) 2018-03-29
JP6768858B2 (ja) 2020-10-14
EP3043772B1 (en) 2023-07-19
JP2019056006A (ja) 2019-04-11
NZ717944A (en) 2021-06-25
IL275388A (en) 2020-07-30
EP4272763A2 (en) 2023-11-08
EP3043776B1 (en) 2024-01-03
CN105705139A (zh) 2016-06-22
AU2023200941A1 (en) 2023-03-30
AU2023229619A1 (en) 2023-10-05
MX2021005907A (es) 2021-06-23
KR20160054009A (ko) 2016-05-13
US20180177876A1 (en) 2018-06-28
AU2023251546A1 (en) 2023-11-16
EP3043774B1 (en) 2020-11-04
AU2014318637B2 (en) 2020-01-23
SI3043775T1 (sl) 2021-01-29
EP4272763A3 (en) 2024-02-14
KR102651018B1 (ko) 2024-03-27
KR102295633B1 (ko) 2021-08-30
AU2020202407A1 (en) 2020-05-07
SG10201806539XA (en) 2018-08-30
MX2021012048A (es) 2021-11-03
AU2020202240B2 (en) 2023-02-09
AU2020202240A1 (en) 2020-04-23
CA2923859A1 (en) 2015-03-19
RU2019140607A3 (ru) 2022-04-18
CA2924069A1 (en) 2015-03-19
JP6774484B2 (ja) 2020-10-21
EP3043775A2 (en) 2016-07-20
JP2019142985A (ja) 2019-08-29
IL244433B (en) 2020-07-30
JP2016534141A (ja) 2016-11-04
RU2016113283A (ru) 2017-10-17
IL244433A0 (en) 2016-04-21
US20180177875A1 (en) 2018-06-28
EP3043776A1 (en) 2016-07-20
MX2016003182A (es) 2017-03-31
AU2020202408A1 (en) 2020-05-07
US20150071925A1 (en) 2015-03-12
CN105705139B (zh) 2019-07-26
ZA201802108B (en) 2022-04-28
SG10201913950XA (en) 2020-03-30
JP2016530321A (ja) 2016-09-29
KR20220123552A (ko) 2022-09-07
IL244430A0 (en) 2016-04-21
MX2016003183A (es) 2016-11-14
JP2016530319A (ja) 2016-09-29
EP3043775B1 (en) 2020-11-04
JP6564512B2 (ja) 2019-08-21
JP2016530318A (ja) 2016-09-29
US10821184B2 (en) 2020-11-03
JP6515105B2 (ja) 2019-05-15
US9833513B2 (en) 2017-12-05
KR20210110396A (ko) 2021-09-07
RU2675824C2 (ru) 2018-12-25
JP2019178176A (ja) 2019-10-17
CA2923844A1 (en) 2015-03-19
KR20240042200A (ko) 2024-04-01
US11819550B2 (en) 2023-11-21
AU2014318725A1 (en) 2016-04-07
HK1225981A1 (zh) 2017-09-22
SG10201809401XA (en) 2018-11-29
US9913905B2 (en) 2018-03-13
CN110559435A (zh) 2019-12-13
JP6463581B2 (ja) 2019-02-06
BR112016005309A8 (pt) 2021-06-22
KR102435648B1 (ko) 2022-08-25
HK1225982A1 (zh) 2017-09-22
ES2959451T3 (es) 2024-02-26
RU2019140607A (ru) 2020-05-29
CN110496099A (zh) 2019-11-26
US20150071922A1 (en) 2015-03-12
SI3043776T1 (sl) 2024-03-29
WO2015038818A3 (en) 2015-07-16
ZA201601968B (en) 2018-07-25
EP3791862A1 (en) 2021-03-17
KR102289825B1 (ko) 2021-08-17
CA2924069C (en) 2021-11-02
CA2923844C (en) 2022-07-26
CN105722501B (zh) 2019-07-26
HK1225979A1 (zh) 2017-09-22
CN105848636B (zh) 2020-02-21
JP2023021352A (ja) 2023-02-10
JP2019073563A (ja) 2019-05-16
CN105722501A (zh) 2016-06-29
SG11201601728YA (en) 2016-04-28
MX2021012050A (es) 2021-11-03
WO2015038777A1 (en) 2015-03-19
IL312865A (en) 2024-07-01
JP2018199735A (ja) 2018-12-20
US9925263B2 (en) 2018-03-27
NZ756260A (en) 2021-06-25
IL275388B1 (en) 2024-06-01
IL244430B (en) 2020-06-30
ZA201801669B (en) 2021-07-28
EP3808338A1 (en) 2021-04-21
AU2020202408B2 (en) 2023-09-21
JP6840797B2 (ja) 2021-03-10
NZ717918A (en) 2021-05-28
ES2837629T3 (es) 2021-07-01
US10179172B2 (en) 2019-01-15
CA2923859C (en) 2021-11-23
AU2014318725A2 (en) 2019-02-14
US10849977B2 (en) 2020-12-01
HK1226309A1 (zh) 2017-09-29
JP6941137B2 (ja) 2021-09-29
CA2923843C (en) 2022-07-12
RU2016113283A3 (ru) 2018-07-27
US20240181063A1 (en) 2024-06-06
MX2021012049A (es) 2021-11-03
EP3043772A1 (en) 2016-07-20
AU2014318696B2 (en) 2020-01-23
AU2014318696A1 (en) 2016-04-07
EP3791862B1 (en) 2024-05-29
US20210030877A1 (en) 2021-02-04
AU2014318691A1 (en) 2016-04-07
CN111202711A (zh) 2020-05-29
US20210038718A1 (en) 2021-02-11
AU2014318637A1 (en) 2016-04-07
RU2710542C2 (ru) 2019-12-27
WO2015038818A2 (en) 2015-03-19
CN110559435B (zh) 2023-10-20
US10821183B2 (en) 2020-11-03
WO2015038782A1 (en) 2015-03-19
JP2020203956A (ja) 2020-12-24
BR112016005309A2 (pt) 2017-08-01
ES2841134T3 (es) 2021-07-07
CN105848636A (zh) 2016-08-10
RU2016113385A (ru) 2017-10-16
CN105722500B (zh) 2019-08-30
CN105722500A (zh) 2016-06-29
CN110496099B (zh) 2022-06-21
JP7214697B2 (ja) 2023-01-30
HK1225980A1 (zh) 2017-09-22
AU2014318725B2 (en) 2020-01-23
AU2020202407B2 (en) 2023-07-13
JP6469113B2 (ja) 2019-02-13
US20150071921A1 (en) 2015-03-12
US20210085792A1 (en) 2021-03-25
WO2015038811A2 (en) 2015-03-19
US20150071920A1 (en) 2015-03-12
ES2972527T3 (es) 2024-06-13
JP6412575B2 (ja) 2018-10-24
SI3043774T1 (sl) 2021-01-29
NZ756401A (en) 2021-05-28
WO2015038811A3 (en) 2015-07-23
EP3043774A2 (en) 2016-07-20
US20180153997A1 (en) 2018-06-07
CN111202711B (zh) 2022-06-21
KR20160055243A (ko) 2016-05-17
US11986526B2 (en) 2024-05-21
CA2923843A1 (en) 2015-03-19
AU2014318691B2 (en) 2020-01-23
SI3043772T1 (sl) 2023-10-30
US10646571B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
IL312865A (en) Liquid protein formulations containing viscosity reducing agents
HK1222557A1 (zh) 的穩定的液體製劑
SG11201508564QA (en) Cleaning liquid composition
EP2955579A4 (en) LIQUID DEVELOPER
HUE039180T2 (hu) Folyékony mosószerkészítmény
ZA201507331B (en) Liquid cleaning composition
EP3041352B8 (en) Cleaning liquid
IL241040A0 (en) Liquid formulations of rascadotril
GB2532663B (en) Liquid mouthwash
SG11201506298YA (en) Liquid container
HK1220366A1 (zh) 蛋白製劑
EP2830607A4 (en) POLYVINYLPYRROLIDONE-BASED ACETAMINOPHONE LIQUID FORMULATIONS
EP2997039A4 (en) STABILIZED LIQUID FORMULATIONS WITH RECEPTORS
EP2997114A4 (en) COMPOSITION BASED ON IONIC LIQUID
GB201315537D0 (en) Liquid mixer
PL2865740T3 (pl) Płynny środek do szorowania
HK1179466A2 (en) Liquid container